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miR-15a andmiR-16-1 were the first microRNAs linked to cancer because their genes are commonly deleted
in human chronic lymphocytic leukemia (CLL). In this issue of Cancer Cell, Klein and coworkers show that
deleting a region with these genes in mouse provides a faithful model for human CLL.Chronic lymphocytic leukemia is the most
frequent leukemia of adults in theWestern
world. Loss of 13q14.3 distal to the retino-
blastoma locus is themost common chro-
mosome aberration in CLL, which is pre-
sented in the majority of cases (Do¨hner
et al., 2000). Studies of clonal evolution
in CLL indicated that heterozygous dele-
tion of 13q14 is an early event, whereas
deletion of the second copy of this region
occurs at a later time point at a lower
frequency (Stilgenbauer et al., 2007).
Mutation analysis of protein-coding genes
in this region revealed no inactivation of
candidate genes. However, a complex
epigenetic regulatory tumor-suppressor
mechanism that would control the expres-
sionof theentire regionandwouldaccount
also for cases without 13q14 deletion has
been proposed (Mertens et al., 2006).
Deletions at 13q14 also occur at high
frequencies in other lymphomas and solid
tumors, such as mantle cell lymphoma,
multiple myeloma, and carcinoma of the
prostate and the lung, suggesting a major
tumor-suppressor mechanism mediated
by this chromosome region.
Calin and coworkers were the first to
show that 13q14 deletion in CLL is associ-ated with downregulation of miR-15a and
miR-16-1, whose genes cluster in the
minimally deleted region (MDR) within
13q14 (Calin et al., 2002). This was the
very first link between miRNAs and
cancer. Because eachmiRNA is expected
to regulate the expression of hundreds
of different genes, several studies have
been carried out to identify the targets of
miR-15a and miR-16-1 (e.g., Calin et al.,
2008). Because the current algorithms
for predicting targets via sequence simi-
larities are imperfect and the effects of
miRNA level changes measured in vitro
are highly dependent on cell systems
used, the physiological relevance of
some of the published targets remains
controversial.
Klein and coworkers now report on the
conclusive functional test of relevant
13q14 genes in mouse models (Klein
et al., 2010). The MDR in 13q14 contains
the noncoding RNA gene DLEU2 with
the miR-15a and miR-16-1 cluster in its
intron 4. Klein and coworkers generated
sophisticated mouse models that have
either deletion of DLEU2 together with
bothmiRNA genes (MDR deleted) or dele-
tion of the twomiRNA genes only. After 15to 18 months, about 5% of the animals
displayed monoclonal B cell lymphocy-
tosis (MBL), which is a possible precursor
to CLL. More importantly, 1/5 of the
MDR-deleted and 1/8 of the miR-15a/
16-1-deleted mice developed CLL or the
related small cell lymphocytic leukemia.
In addition, 9% of the MDR-deleted and
2% of the miR-15a/16-1-deleted animals
developed a phenotype reminiscent of
human diffuse large B cell lymphoma
(DLBCL), a disease known to progress
from CLL at low frequency. Thus, the
deletion of the MDR caused B cell lym-
phoproliferative disorders, nicely recapit-
ulating the spectrum of human CLL
phenotypes.
Notably, the MDR-deleted mice died
significantly earlier than did their wild-
type littermates whereas miR-15a/16-1
deletion alone did not result in survival
differences. Thus, although both MDR-
deleted and miR-15/16-deleted mice
develop an indolent disease reminiscent
of CLL, there is at least one genetic
element within the MDR other than miR-
15a/16-1 that modulates the aggressive-
ness of the disease. DLEU2 and the first
exon of DLEU1 are the only known17, January 19, 2010 ª2010 Elsevier Inc. 3
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Previewstranscribed sequences in the MDR
interval besides miR-15a/16-1, and both
genes generate transcripts that are not
translated. Thus, the tumor-suppressor
mechanism mediated within 13q14
clearly involves miRNAs as well as other
noncoding RNAs.
The borders of the MDR were deter-
mined by comparing many CLL cases
with 13q14 deletion. However, the vast
majority of CLLs displaymuch larger dele-
tions. Interestingly, CLLs having the
13q14 deletion as the sole genetic abnor-
mality have a favorable course of disease
(Do¨hner et al., 2000). This is in sharp
contrast to the poor prognosis of multiple
myeloma, in which the same chromo-
some region is often deleted but is
through a loss of the entire chromosome
13 in most of those cases. Thus, because
sequences other than the miR-15a/16-1
cluster within the MDR are responsible
for aggressiveness of CLL, sequence
elements distant from the MDR on chro-
mosome 13 seem to also seriously affect
the clinical behavior.
Klein et al. also performed in vitro anal-
ysis of miR-15a/16-1 and DLEU2 by
re-expressing them in a CLL cell line.
Expression of DLEU2 had no effect on
cell proliferation whereas expression of
miR-15a/16-1 remarkably reduced cell
proliferation and decreased expression
of multiple genes involved in G0/G1-S
phase transition, many of which are pre-
dicted to be targets of miR-15a/16-1.
Failure of apoptosis induction is another
important process in the pathophysiology
of CLL (Korz et al., 2002). However, the
in vitro studies by Klein et al. did not
provide evidence for a role of these
miRNAs in regulating antiapoptotic
players such as BCL2 or NF-kB. Thus,
deletion of miR-15a/16-1 seems to accel-
erate proliferation of B cells by regulating
genes that control progression through
the cell cycle. Similarly, a study on the
role of miR-15a/16-1 in the pathogenesis
of prostate cancer revealed CCND1 and
WNT3A transcripts as their targets and
deletion of these miRNA genes promoting4 Cancer Cell 17, January 19, 2010 ª2010 Elsurvival, proliferation, and invasion (Bonci
et al., 2008). Furthermore, analysis of
miR-15a/16-1 deletion in non-small cell
lung cancer revealed a dominant role in
cell cycle progression (Bandi et al.,
2009). In this context it should be
mentioned that, interestingly, the mouse
models reported by Klein et al., which
were deficient of MDR or miR-15a/16-1
in every cell, did not so far reveal evidence
for neoplasms other than B cell lympho-
proliferative diseases.
The pathophysiology of CLL shows
a number of features that would make it
very difficult to reproduce in a mouse
model. (1) CLL is primarily a disease of
elderly people. (2) It is an indolent
lymphoma with high clinical heteroge-
neity, with many patients surviving for
many years without serious symptoms.
(3) It seems to be divided into two disease
subclasses with pre- and postgerminal
center B cell lymphocytes affected. (4) It
has been suggested that a common
antigen is involved in the etiology of CLL.
All these features seem to be represented
in the mouse models of Klein and
coworkers. With the occurrence of the
potential CLL precursor MBL, of CLL
and small cell lymphocytic leukemia, and
of a phenotype equivalent to DLBCL
known to occasionally progress from
CLL, the full variety of CLL-related
diseases is present in these models.
Furthermore, the disease occurs at
advanced age with an indolent course,
with the deletion of miRNAs alone not
affecting survival of the organism. Based
on the mutation analysis of immunoglob-
ulin genes, it is evident that pre- as well
as postgerminal center lymphocytes can
be affected. Another highly interesting
finding of the study is that detailed anal-
ysis of the immunoglobulin heavy chain
revealed that both MDR-deleted and
miR-15a/16-1-deleted mice can express
antibodies with stereotypical antigen
binding regions, a feature that is known
for human CLL and is believed to indicate
the existence of common CLL-inducing
antigens or autoantigens.sevier Inc.Thus, these mice carrying deletion of
the relevant chromosomal region in
13q14mimic the biology of CLL in a highly
intriguing manner, making them faithful
animal models for CLL and superior to
previously reported models. They also
provide a paradigm for tumor-suppres-
sion mechanisms by noncoding RNAs,
including miRNAs. Detailed characteriza-
tion of these animal models will improve
our understanding of the pathophysiology
of CLL and related diseases. In addition,
they might also become useful tools for
testing novel therapy regimens.REFERENCES
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